Medtronic announces Infuse spine trial

By

Medtronic (NYSE:MDT) said today that it won FDA approval for a clinical trial of its Infuse bone graft in transforaminal lumbar interbody fusion spine procedures.

The Minneapolis-based company started recruiting for the prospective, randomized pivotal trial, which is slated to enroll up to 1,000 patients. The TLIF trial would be the second clinical trial for Infuse, after the FDA approved a separate study in 2017 for posterolateral fusion procedures, which is still enrolling patients. If you want to read more about this news, click here. 

Posted in News.
Share

Deja una respuesta

Tu dirección de correo electrónico no será publicada.

Related Posts

  •
    24 agosto, 2020

    COFEPRIS Evolves

  •
    10 octubre, 2019

    AI-enhanced ECGs may soon assess overall health

    Scientists have trained an artificial intelligence tool to predict sex and estimate age from electrocardiogram readouts. They suggest that, with further development, the tool could soon be helping doctors to assess the overall health of their patients. An electrocardiogram, also known as an ECG or EKG, is a painless, simple test that records the electrical …

  •
    18 junio, 2019

    5 Pediatric Orthopedic Devices you need to know

    The National Capital Consortium for Pediatric Device Innovation recently recognized five pediatric orthopedic devices that could improve scoliosis treatment, clubfoot assessment, and surgical imaging. If you want to read more about this news click here.

  •
    10 octubre, 2019

    Human trials could start soon on Adam’s 3D printed bone grafts

    Adam — a young company with technology to 3D print bone grafts made out of ceramic bioglass and modified biopolymer — said today that it expects first human trials to start by the end of the year. Officials at the Groton, Conn.– and Odessa, Ukraine–based company expect preclinical trials to finish this month. The Adam technology …